VANCOUVER, BC / ACCESSWIRE / August 6, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC PINK:XPHYF) ('XPhyto' or the 'Company'), a next generation bioscience company, is pleased to announce that it will be presenting at Wall Street Reporter's 'Next Super Stock' livestream conference on Monday, August 10^th, 2020.

Mr. Hugh Rogers, CEO of XPhyto will share an overview of the depth and diversity of the growing pipeline of drug delivery and screening test products, its strategic alliances, including that with 3a-diagnostics GmbH, and the status of its COVID-19 rapid screening test development program and the pathway to commercialisation.

The XPhyto presentation will take place at 12:30 pm EST on Monday, August 10^th, 2020.

Following the 20-minute presentation, Mr. Rogers will take questions from the audience.

To sign up for the conference visit: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/.

Recent company highlights include:

• COVID-19 rapid screening test prototype validation
  • Visual results in less than 10 minutes
  • Low cost and disposable
  • No specialized training, laboratory equipment or consumables required
  • No RNA amplification required
• Infectious disease biosensors successfully incorporated into XPhyto's dissolvable oral delivery platform
  • Delivery of novel peptide-based biosensors for viral and bacterial infections: H1N1 (swine flu), H5N1, (avian flu), influenza A, scarlet fever, stomatitis, periimplantitis, and periodontitis
• Novel CBD-based dissolvable oral drug delivery therapeutic for epilepsy and Rotigotine-based transdermal patch for Parkinson's both advancing to human bioavailability studies.

About 'Next Super Stock Live!' conference: Wall Street Reporter's 'NEXT SUPER STOCK Live!' conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth in the months ahead.

To view the conference visit: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/.

About XPhyto Therapeutics Corp.

XPhyto is a diversified bioscience company with strategic assets and investments in the field of next generation drug delivery and rapid pathogen screening systems, as well as medical cannabis opportunities focused on European markets. Through its 100% owned subsidiaries and exclusive collaboration agreements, XPhyto is pursuing clinical programs for the transdermal and dissolvable oral delivery of conventional and cannabis based narcotics for neurological applications, as well as rapid dissolvable oral biosensor and lateral flow assay-based screening tests for dental health applications and high-risk pandemic threats such as COVID-19, H1N1 (swine flu) and H5N1 (avian flu). XPhyto has two exclusive cannabis collaborations with the Technical University of Munich, and two exclusive 5-year engagements with the University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences for cannabis extraction, isolation, formulation, and analytical testing.

For further information, please contact:

Hugh Rogers
CEO & Director
+1.780.818.6422
[email protected]
www.xphyto.com

Wolfgang Probst
Director
+49 8331 9948 122
[email protected]
www.xphyto.com